# Xencor

Source: https://onco.cc/companies/xencor/  
OnCo record `xencor` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Xencor is an antibody-engineering company (XmAb Fc technology) developing 2+1 T-cell engagers for kidney cancer (ENPP3) and ovarian/germ-cell tumours (CLDN6).

## Summary

Xencor, based in Pasadena and listed as XNCR, is an antibody engineering company built on its XmAb Fc technology, developing 2+1 format T-cell engagers for kidney cancer, targeting ENPP3, and for ovarian and germ-cell tumours, targeting Claudin 6. XmAb819, an ENPP3 by CD3 engager, is in clear-cell renal cell carcinoma with a pivotal study planned for 2027, XmAb541, a Claudin 6 by CD3 engager, has produced confirmed partial responses in ovarian and germ-cell tumours, and the XmAb Fc technology is licensed into several approved antibodies. OnCo links it to renal cell carcinoma and ovarian cancer, to T-cell engagers and bispecific antibodies, and to CD3 as a target. Whether T-cell engagers can work in solid tumours without unacceptable toxicity is the question its 2+1 format is designed to answer. The T-cell engager page carries the field.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Pasadena, CA
- Type: biotech
- Website: https://xencor.com
- Ticker: XNCR

## Sources

- 2026 milestones: https://investors.xencor.com/news-releases/news-release-details/xencor-highlights-corporate-priorities-and-2026-pipeline

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/)
- drugs: [Vudalimab](https://onco.cc/drugs/vudalimab/)
- trials: [A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies](https://onco.cc/trials/nct05032040/)

---
JSON: https://onco.cc/api/v1/entities/xencor.json